BILB 1941 ZW

BILB 1941 ZW is a small molecule non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. Developed by Boehringer Ingelheim, it was primarily investigated for the treatment of chronic hepatitis C virus infection, specifically genotype 1. In Phase 1/2 clinical trials, the drug was administered as an oral solution every 8 hours. Although it demonstrated antiviral activity, particularly in subtype 1b, its development was discontinued due to dose-limiting gastrointestinal side effects, most notably diarrhea, which prevented the escalation to therapeutic doses required for optimal efficacy.

Other names

494856-61-03WV68DY85W(E)-3-[4-[[1-[(3-cyclopentyl-1-methyl-2-pyridin-2-ylindole-6-carbonyl)amino]cyclobutanecarbonyl]amino]phenyl]prop-2-enoic acid